Walder Wyss with TECregen on CHF 10 m funding round
Walder Wyss advised TECregen, as the Basel-based biotechnology company raised CHF 10 million in a seed financing round.
The investor base
Boehringer Ingelheim Venture Fund (BIVF) led the round in question, with participation from LifeSpan Vision Ventures, Carma Fund, EOS BioInnovation, HighTech Gründerfonds (HTGF), the JFG Life Sciences Foundation of the University of Basel, and Zurich Cantonal Bank.
The Walder Wyss team
Partner Alexander Gutmans (corporate/M&A and venture capital, pictured left) and senior associate Christoph Burckhardt (M&A and venture capital, pictured right) led the Walder Wyss team on the matter, working alongside managing associate Karina Tschon (corporate/M&A and venture capital) and associate Oerjan Wickart (corporate/M&A and venture capital).
